AustralieFrV1, PubMed, Corpus, bibRecord, 003B08

Reply: Comment on 'Beta-blockers increase response to chemotherapy via direct anti-tumour and anti-angiogenic mechanisms in neuroblastoma'--β-blockers are potent anti-angiogenic and chemo-sensitising agents, rather than cytotoxic drugs.

Identifieur interne : 003B08 ( PubMed/Corpus ); précédent : 003B07; suivant : 003B09

Reply: Comment on 'Beta-blockers increase response to chemotherapy via direct anti-tumour and anti-angiogenic mechanisms in neuroblastoma'--β-blockers are potent anti-angiogenic and chemo-sensitising agents, rather than cytotoxic drugs.

Auteurs : E. Pasquier ; N. Andre ; T. Trahair ; M. Kavallaris

Source :

British journal of cancer [ 1532-1827 ] ; 2013.

RBID : pubmed:23969728

English descriptors

KwdEn :
- Abdominal Neoplasms (drug therapy), Adrenergic beta-Antagonists (therapeutic use), Angiogenesis Inhibitors (therapeutic use), Animals, Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Humans, Neuroblastoma (drug therapy).
MESH :
- chemical , therapeutic use : Adrenergic beta-Antagonists, Angiogenesis Inhibitors.
- drug therapy : Abdominal Neoplasms, Neuroblastoma.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Animals, Humans.

DOI: 10.1038/bjc.2013.498
PubMed: 23969728

Links to Exploration step

pubmed:23969728

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reply: Comment on 'Beta-blockers increase response to chemotherapy via direct anti-tumour and anti-angiogenic mechanisms in neuroblastoma'--β-blockers are potent anti-angiogenic and chemo-sensitising agents, rather than cytotoxic drugs.</title>
<author><name sortKey="Pasquier, E" sort="Pasquier, E" uniqKey="Pasquier E" first="E" last="Pasquier">E. Pasquier</name>
<affiliation><nlm:affiliation>1] Children's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia [2] Metronomics Global Health Initiative, Marseille 13005, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Andre, N" sort="Andre, N" uniqKey="Andre N" first="N" last="Andre">N. Andre</name>
</author>
<author><name sortKey="Trahair, T" sort="Trahair, T" uniqKey="Trahair T" first="T" last="Trahair">T. Trahair</name>
</author>
<author><name sortKey="Kavallaris, M" sort="Kavallaris, M" uniqKey="Kavallaris M" first="M" last="Kavallaris">M. Kavallaris</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23969728</idno>
<idno type="pmid">23969728</idno>
<idno type="doi">10.1038/bjc.2013.498</idno>
<idno type="wicri:Area/PubMed/Corpus">003B08</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003B08</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Reply: Comment on 'Beta-blockers increase response to chemotherapy via direct anti-tumour and anti-angiogenic mechanisms in neuroblastoma'--β-blockers are potent anti-angiogenic and chemo-sensitising agents, rather than cytotoxic drugs.</title>
<author><name sortKey="Pasquier, E" sort="Pasquier, E" uniqKey="Pasquier E" first="E" last="Pasquier">E. Pasquier</name>
<affiliation><nlm:affiliation>1] Children's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia [2] Metronomics Global Health Initiative, Marseille 13005, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Andre, N" sort="Andre, N" uniqKey="Andre N" first="N" last="Andre">N. Andre</name>
</author>
<author><name sortKey="Trahair, T" sort="Trahair, T" uniqKey="Trahair T" first="T" last="Trahair">T. Trahair</name>
</author>
<author><name sortKey="Kavallaris, M" sort="Kavallaris, M" uniqKey="Kavallaris M" first="M" last="Kavallaris">M. Kavallaris</name>
</author>
</analytic>
<series><title level="j">British journal of cancer</title>
<idno type="eISSN">1532-1827</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abdominal Neoplasms (drug therapy)</term>
<term>Adrenergic beta-Antagonists (therapeutic use)</term>
<term>Angiogenesis Inhibitors (therapeutic use)</term>
<term>Animals</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Humans</term>
<term>Neuroblastoma (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic beta-Antagonists</term>
<term>Angiogenesis Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Abdominal Neoplasms</term>
<term>Neuroblastoma</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23969728</PMID>
<DateCreated><Year>2013</Year>
<Month>10</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted><Year>2013</Year>
<Month>12</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>04</Month>
<Day>23</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-1827</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>109</Volume>
<Issue>7</Issue>
<PubDate><Year>2013</Year>
<Month>Oct</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>British journal of cancer</Title>
<ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Reply: Comment on 'Beta-blockers increase response to chemotherapy via direct anti-tumour and anti-angiogenic mechanisms in neuroblastoma'--β-blockers are potent anti-angiogenic and chemo-sensitising agents, rather than cytotoxic drugs.</ArticleTitle>
<Pagination><MedlinePgn>2024-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2013.498</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pasquier</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>1] Children's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia [2] Metronomics Global Health Initiative, Marseille 13005, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Andre</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Trahair</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kavallaris</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType>
<PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>08</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Br J Cancer</MedlineTA>
<NlmUniqueID>0370635</NlmUniqueID>
<ISSNLinking>0007-0920</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Mar 20;26(9):1504-10</RefSource>
<PMID Version="1">18349403</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 May;14(6):e239-48</RefSource>
<PMID Version="1">23639324</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Jun 12;358(24):2649-51</RefSource>
<PMID Version="1">18550886</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Mar 1;27(7):1034-40</RefSource>
<PMID Version="1">19171711</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Mar 1;27(7):1026-33</RefSource>
<PMID Version="1">19171713</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Sep 30;363(14):1313-23</RefSource>
<PMID Version="1">20879880</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Feb 1;29(4):449-55</RefSource>
<PMID Version="1">21172879</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oncotarget. 2010 Nov;1(7):628-38</RefSource>
<PMID Version="1">21317458</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Intern Med. 2011 Apr 25;171(8):779-81</RefSource>
<PMID Version="1">21518948</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Jul 1;29(19):2645-52</RefSource>
<PMID Version="1">21632501</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Jul 1;29(19):2635-44</RefSource>
<PMID Version="1">21632503</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2273-9</RefSource>
<PMID Version="1">21933972</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oncotarget. 2011 Oct;2(10):797-809</RefSource>
<PMID Version="1">22006582</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 May 20;30(15):1842-8</RefSource>
<PMID Version="1">22529259</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2012 Nov;127(2):375-8</RefSource>
<PMID Version="1">22819786</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2013 May;24(5):1312-9</RefSource>
<PMID Version="1">23300016</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2013 Jun 25;108(12):2485-94</RefSource>
<PMID Version="1">23695022</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2013 Oct 1;109(7):2022-3</RefSource>
<PMID Version="1">23969727</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentOn"><RefSource>Br J Cancer. 2013 Jun 25;108(12):2485-94</RefSource>
<PMID Version="1">23695022</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentOn"><RefSource>Br J Cancer. 2013 Oct 1;109(7):2022-3</RefSource>
<PMID Version="1">23969727</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000008" MajorTopicYN="N">Abdominal Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000319" MajorTopicYN="N">Adrenergic beta-Antagonists</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC3790159</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>8</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>8</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2013</Year>
<Month>12</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23969728</ArticleId>
<ArticleId IdType="pii">bjc2013498</ArticleId>
<ArticleId IdType="doi">10.1038/bjc.2013.498</ArticleId>
<ArticleId IdType="pmc">PMC3790159</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B08 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003B08 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:23969728
   |texte=   Reply: Comment on 'Beta-blockers increase response to chemotherapy via direct anti-tumour and anti-angiogenic mechanisms in neuroblastoma'--β-blockers are potent anti-angiogenic and chemo-sensitising agents, rather than cytotoxic drugs.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:23969728" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Reply: Comment on 'Beta-blockers increase response to chemotherapy via direct anti-tumour and anti-angiogenic mechanisms in neuroblastoma'--β-blockers are potent anti-angiogenic and chemo-sensitising agents, rather than cytotoxic drugs.

Reply: Comment on 'Beta-blockers increase response to chemotherapy via direct anti-tumour and anti-angiogenic mechanisms in neuroblastoma'--β-blockers are potent anti-angiogenic and chemo-sensitising agents, rather than cytotoxic drugs.

Source :

English descriptors

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki